title: Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice.
abstract: BACKGROUND
  Recent evidence suggests that in addition to controlling emotional behavior in general, endocannabinoid signaling is engaged in shaping behavioral responses to challenges. This important function of endocannabinoids is still poorly understood.
  
  
  OBJECTIVE
  Here we investigated the impact of blockade of fatty acid amide hydrolase (FAAH), the degrading enzyme of anandamide on behavioral responses induced by challenges of different intensity.
  
  
  METHODS
  Mice treated with FAAH inhibitor URB597 were either manually restrained on their backs (back test) or received foot-shocks.
  
  
  RESULTS
  The behavior of mice showed bimodal distribution in the back test: they either predominantly showed escape attempts or equally distributed time between passivity and escape. URB597 increased escapes in animals with low escape scores. No effects were noticed in mice showing high escape scores, which is likely due to a ceiling effect. We hypothesized that stronger stressors would wash out individual differences in coping; therefore, we exposed mice to foot-shocks that decreased locomotion and increased freezing in all mice. URB597 ameliorated both responses. The re-exposure of mice to the shock cage 14 days later without delivering shocks or treatment was followed by reduced and fragmented sleep as shown by electrophysiological recordings. Surprisingly, sleep was more disturbed after the reminder than after shocks in rats receiving vehicle before foot-shocks. These reminder-induced disturbances were abolished by URB597 administered before shocks.
  
  
  CONCLUSIONS
  These findings suggest that FAAH blockade has an important role in the selection of behavioral responses under challenging conditions and-judging from its long-term effects-that it influences the cognitive appraisal of the challenge.
authors.affiliation: Department of Behavioural Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, P.O. Box 67, 1450, Budapest, Hungary, haller.jozsef@koki.mta.hu.
authors.forename: Jozsef
authors.initials: J
authors.lastname: Haller
authors.forename: Mano
authors.initials: M
authors.lastname: Aliczki
authors.forename: Katalin Gyimesine
authors.initials: KG
authors.lastname: Pelczer
authors.forename: Klaudia
authors.initials: K
authors.lastname: Spitzer
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Balogh
authors.forename: Sandor
authors.initials: S
authors.lastname: Kantor
mesh_terms: D000223:Adaptation, Psychological / Q000187:drug effects* / Q000502:physiology; D000581:Amidohydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D001549:Benzamides / Q000494:pharmacology*; D002219:Carbamates / Q000494:pharmacology*; D004567:Electrodes, Implanted; D004569:Electroencephalography; D004576:Electromyography; D004597:Electroshock; D063388:Endocannabinoids / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004924:Escape Reaction / Q000187:drug effects / Q000502:physiology; D046352:Freezing Reaction, Cataleptic / Q000187:drug effects / Q000502:physiology; D008297:Male; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D012149:Restraint, Physical; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D013315:Stress, Psychological / Q000188:drug therapy* / Q000503:physiopathology; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001095:Arachidonic Acids; D001549:Benzamides; D002219:Carbamates; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D053284:Polyunsaturated Alkamides; D000099252:Fatty Acid Amide Hydrolases; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; C078814:anandamide
references.citation: Schizophr Res. 2007 Aug;94(1-3):12-22
references.pmid: 17561377
references.citation: Sleep. 2009 Sep;32(9):1127-34
references.pmid: 19750917
references.citation: Neuroscience. 2001;106(1):1-4
references.pmid: 11564411
references.citation: Front Behav Neurosci. 2012 Mar 20;6:11
references.pmid: 22454620
references.citation: Pharmacol Res. 2011 Sep;64(3):226-34
references.pmid: 21600985
references.citation: J Neurol. 2011 Jan;258(1):37-43
references.pmid: 20658245
references.citation: Stress. 2010 Mar;13(2):172-83
references.pmid: 20214438
references.citation: Psychopharmacology (Berl). 2009 Jul;204(4):607-16
references.pmid: 19259645
references.citation: Physiol Behav. 2009 Jun 22;97(3-4):385-93
references.pmid: 19303031
references.citation: Ann N Y Acad Sci. 2006 Dec;1094:319-24
references.pmid: 17347369
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
references.pmid: 15579492
references.citation: Learn Mem. 2009 Apr 29;16(5):332-7
references.pmid: 19403796
references.citation: Neuropharmacology. 2011 Feb-Mar;60(2-3):235-43
references.pmid: 20850463
references.citation: Pharmacol Biochem Behav. 2013 Apr;105:166-72
references.pmid: 23474373
references.citation: Sleep. 2003 Aug 1;26(5):527-40
references.pmid: 12938805
references.citation: Brain Behav Evol. 2007;70(4):218-26
references.pmid: 17914253
references.citation: Eur Neuropsychopharmacol. 2012 Sep;22(9):664-71
references.pmid: 22325231
references.citation: Front Behav Neurosci. 2011 Sep 13;5:57
references.pmid: 21949506
references.citation: Eur J Neurosci. 2002 Oct;16(7):1395-8
references.pmid: 12405999
references.citation: Pharmacol Biochem Behav. 2005 Jun;81(2):331-42
references.pmid: 15927244
references.citation: Neuropsychopharmacology. 2007 Feb;32(2):298-308
references.pmid: 16760924
references.citation: Psychopharmacology (Berl). 2013 Dec;230(3):353-62
references.pmid: 23743650
references.citation: Eur J Neurosci. 2005 Feb;21(4):1077-80
references.pmid: 15787712
references.citation: Br J Pharmacol. 2007 Dec;152(7):1092-101
references.pmid: 17876302
references.citation: J Neurosci. 2012 Oct 24;32(43):14899-908
references.pmid: 23100412
references.citation: Behav Pharmacol. 2012 Aug;23(4):348-57
references.pmid: 22750842
references.citation: Behav Genet. 1984 May;14(3):195-208
references.pmid: 6541476
references.citation: Physiol Behav. 2001 Jul;73(4):541-51
references.pmid: 11495658
references.citation: CNS Drug Rev. 2006 Spring;12(1):21-38
references.pmid: 16834756
references.citation: J Psychopharmacol. 2012 Oct;26(10):1317-32
references.pmid: 22495620
references.citation: Neurosci Biobehav Rev. 1999 Nov;23(7):925-35
references.pmid: 10580307
references.citation: Dev Psychobiol. 1981 Mar;14(2):101-7
references.pmid: 7202847
references.citation: Nat Med. 2003 Jan;9(1):76-81
references.pmid: 12461523
references.citation: Hippocampus. 2010 Oct;20(10):1126-38
references.pmid: 19830813
references.citation: J Neurosci. 2012 May 23;32(21):7109-18
references.pmid: 22623656
references.citation: Br J Pharmacol. 1980 Nov;70(3):367-73
references.pmid: 7192165
references.citation: Behav Pharmacol. 2005 Sep;16(5-6):315-31
references.pmid: 16148437
references.citation: Neuropsychopharmacology. 2013 Jun;38(7):1276-86
references.pmid: 23340520
references.citation: Behav Brain Res. 2011 Jun 20;220(1):140-5
references.pmid: 21295077
references.citation: Eur J Neurosci. 2004 Apr;19(7):1906-12
references.pmid: 15078564
references.citation: Behav Pharmacol. 2011 Jun;22(3):191-202
references.pmid: 21512341
references.citation: Psychopharmacology (Berl). 2007 May;192(1):61-70
references.pmid: 17279376